DKK1,622.00
1.53% yesterday
Copenhagen, Sep 27, 05:00 pm CET
ISIN
DK0010272202
Symbol
GMAB
Sector

Genmab A/S Stock price

DKK1,622.00
-240.00 12.89% 1M
-462.00 22.17% 6M
-533.00 24.73% YTD
-894.00 35.53% 1Y
-1,111.00 40.65% 3Y
+222.00 15.86% 5Y
+1,370.00 543.65% 10Y
Copenhagen, Closing price Fri, Sep 27 2024
+24.50 1.53%
ISIN
DK0010272202
Symbol
GMAB
Sector

Key metrics

Market capitalization DKK101.45b
Enterprise Value DKK86.74b
P/E (TTM) P/E ratio 18.90
EV/FCF (TTM) EV/FCF 13.31
EV/Sales (TTM) EV/Sales 4.57
P/S ratio (TTM) P/S ratio 5.35
P/B ratio (TTM) P/B ratio 3.27
Revenue growth (TTM) Revenue growth 15.89%
Revenue (TTM) Revenue DKK18.97b
EBIT (operating result TTM) EBIT DKK6.00b
Free Cash Flow (TTM) Free Cash Flow DKK6.52b
Cash position DKK15.73b
EPS (TTM) EPS DKK84.54
P/E forward 18.77
P/S forward 4.80
EV/Sales forward 4.10
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

16x Buy
62%
9x Hold
35%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

Buy
62%
Hold
35%
Sell
4%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
18,967 18,967
16% 16%
100%
- Direct Costs 601 601
-
3%
18,366 18,366
-
97%
- Selling and Administrative Expenses 3,524 3,524
13% 13%
19%
- Research and Development Expense 8,838 8,838
31% 31%
47%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6,004 6,004
8% 8%
32%
Net Profit 5,502 5,502
16% 16%
29%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,204
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today